Madrigal Pharmaceuticals
MDGL
97 hedge funds and large institutions have $148M invested in Madrigal Pharmaceuticals in 2015 Q2 according to their latest regulatory filings, with 19 funds opening new positions, 38 increasing their positions, 24 reducing their positions, and 13 closing their positions.
58% more repeat investments, than reductions
Existing positions increased: 38 | Existing positions reduced: 24
46% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 13
7% more funds holding
Funds holding: 91 → 97 (+6)
3% more capital invested
Capital invested by funds: $144M → $148M (+$4.66M)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
31% less call options, than puts
Call options by funds: $695K | Put options by funds: $1.01M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$2.06M |
| 2 |
CCA
Catalyst Capital Advisors
Huntington,
New York
|
+$959K |
| 3 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
+$908K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$560K |
| 5 |
D.E. Shaw & Co
New York
|
+$556K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$6.29M |
| 2 |
JG
Jefferies Group
New York
|
-$6.29M |
| 3 |
UOC
UBS O'Connor
Chicago,
Illinois
|
-$1.94M |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$1.55M |
| 5 |
Renaissance Technologies
New York
|
-$1.27M |
MDGL Hedge Fund Activity: Q2 2015 in Review
97 of the 3,730 institutional investors tracked by Wall St. Rank reported a position in Madrigal Pharmaceuticals (MDGL) for Q2 2015, worth a combined $148M — up 3.2% from $144M a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new MDGL positions and 13 closed out — a net gain of 6 holders — while 38 added to existing stakes and 24 trimmed.
The largest buyer was BlackRock Fund Advisors, adding an estimated $2.06M. The largest seller was Armistice Capital, exiting entirely with an estimated $6.29M sold.
- 97 institutional investors held Madrigal Pharmaceuticals (MDGL) as of Q2 2015, up from 91 in Q1 2015.
- Funds reported $148M of Madrigal Pharmaceuticals stock for Q2 2015, up 3.2% quarter-over-quarter.
- 19 funds opened new Madrigal Pharmaceuticals positions in Q2 2015 and 13 closed out, a net change of +6 holders.
- The largest Madrigal Pharmaceuticals buyer in Q2 2015 was BlackRock Fund Advisors, an estimated $2.06M added.
- The largest Madrigal Pharmaceuticals seller in Q2 2015 was Armistice Capital, an estimated $6.29M sold.
Based on aggregated 13F filings for Q2 2015.